Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations

详细信息    查看全文

• 作者：Teresa C. Longoria ; Krishnansu S. Tewari
• 刊名：Drugs
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：75
• 期：16
• 页码：1853-1865
• 全文大小：2,065 KB
• 参考文献：1.Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012. http://?globocan.?iarc.?fr/?old/?FactSheets/?cancers/?cervix-new.?asp . Accessed 16 Sep 2015.
  2.Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007-012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004-.PubMed
  3.Rahman M, McGrath CJ, Hirth JM, Berenson AB. Age at HPV vaccine initiation and completion among US adolescent girls: trend from 2008 to 2012. Vaccine. 2015;33(5):585-.CrossRef PubMed
  4.Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012;30(24):3546-6.CrossRef PubMed
  5.What are the key statistics about cervical cancer? http://?www.?cancer.?org/?cancer/?cervicalcancer/?detailedguide/?cervical-cancer-key-statistics . Accessed 26 Feb 2015.
  6.DiSaia P, Creasman W. Clinical gynecologic oncology. 8th ed. Philadelphia: Elsevier; 2012.
  7.Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48(4):899-03.CrossRef PubMed
  8.Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(15):3113-.CrossRef PubMed
  9.Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626-3.CrossRef PubMed
  10.Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014;26(4):314-1.CrossRef PubMed
  11.Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606-3.PubMed
  12.Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154-1.CrossRef PubMed
  13.Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-8.PubMed
  14.Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-3.CrossRef PubMed
  15.Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-3.CrossRef PubMed
  16.National Institutes of Health. NCI issues clinical announcement for cervical cancer: chemotherapy plus radiation improves survival. http://?www.?nih.?gov/?news/?pr/?feb99/?nci-22.?htm . Accessed 26 Feb 2015.
  17.Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649-5.PubMedCentral CrossRef PubMed
  18.Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-3.PubMedCentral CrossRef PubMed
  19.Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001;48(3):188-6.CrossRef PubMed
  20.Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92(2):635-.CrossRef PubMed
  21.Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(7):1069-4.PubMedCentral CrossRef PubMed
  22.Bodily JM, Mehta KP, Laimins LA. Human papillomavirus E7 enhances
• 作者单位：Teresa C. Longoria (1)
  Krishnansu S. Tewari (1)
  
  1. University of California, Irvine Medical Center, 101 The City Drive South, Bldg 56, Orange, CA, 92868, USA
  
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1950

文摘

As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of advanced forms of this disease. In this review, we explore the evolution of the treatment of metastatic, recurrent, and persistent cervical cancer from cytotoxic agents to targeted therapy. We discuss why targeted therapies are unlikely to produce sustained responses alone but may be more successful in combination with immunotherapies. We also provide a rationale for the potential next phase in treatment of this challenging disease—combined therapy with antiangiogenic agents and immune checkpoint inhibitors. In doing so, we highlight recent paradigm shifts within cancer therapeutics, including the shift in focus from the tumor cell itself to the tumor microenvironment, and from stimulating the immune system to inhibiting the inhibitors of an adequate immune response.